92643-72-6

Basic information

• Product Name: Methyl 3-amino-4-hydroxy-5-methoxybenzenecarboxylate
• Synonyms: Methyl 3-amino-4-hydroxy-5-methoxybenzenecarboxylate;2-Amino-6-methoxy-4-(methoxycarbonyl)phenol, 2-Hydroxy-3-methoxy-5-(methoxycarbonyl)aniline;Methyl 3-amino-4-hydroxy-5-methoxybenzoate 95+%;methyl 3-amino-4-hydroxy-5-methoxybenzoate;3-Amino-4-hydroxy-5-methoxy-benzoic acid methyl ester
• CAS NO: 92643-72-6
• Molecular Formula: C₉H₁₁NO₄
• Molecular Weight: 197
• Mol File: 92643-72-6.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methyl 3-amino-4-hydroxy-5-methoxybenzenecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3-amino-4-hydroxy-5-methoxybenzenecarboxylate(92643-72-6)
• EPA Substance Registry System: Methyl 3-amino-4-hydroxy-5-methoxybenzenecarboxylate(92643-72-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 92643-72-6(Hazardous Substances Data)

Usage

General Description

Methyl 3-amino-4-hydroxy-5-methoxybenzenecarboxylate is an organic compound with the chemical formula C10H11NO5. It is commonly used as a building block in organic synthesis and pharmaceutical research. This chemical compound is a derivative of 3-amino-4-hydroxy-5-methoxybenzoic acid and is often utilized in the production of pharmaceutical drugs due to its potential pharmacological properties. It is also used in the research and development of various medicinal compounds and is an important intermediate in the synthesis of a wide range of organic compounds. Additionally, it may have applications in the development of agrochemicals and other specialty chemicals.

InChI:InChI=1/C9H11NO4/c1-13-7-4-5(9(12)14-2)3-6(10)8(7)11/h3-4,11H,10H2,1-2H3

Upstream product

• 3943-74-6 4-hydroxy-3-methoxybenzoic acid methyl ester 
• 42590-00-1 4-hydroxy-3-methoxy-5-nitrobenzoic acid methyl ester 
• 121-34-6 3-methoxy-4-hydroxybenzoic acid 

Relevant articles and documents

Design, Synthesis, and Pharmacological Characterization of a Neutral, Non-Prodrug Thrombin Inhibitor with Good Oral Pharmacokinetics

Despite extensive research on small molecule thrombin inhibitors for oral application in the past decades, only a single double prodrug with very modest oral bioavailability has reached human therapy as a marketed drug. We have undertaken major efforts to identify neutral, non-prodrug inhibitors. Using a holistic analysis of all available internal data, we were able to build computational models and apply these for the selection of a lead series with the highest possibility of achieving oral bioavailability. In our design, we relied on protein structure knowledge to address potency and identified a small window of favorable physicochemical properties to balance absorption and metabolic stability. Protein structure information on the pregnane X receptor helped in overcoming a persistent cytochrome P450 3A4 induction problem. The selected compound series was optimized to a highly potent, neutral, non-prodrug thrombin inhibitor by designing, synthesizing, and testing derivatives. The resulting optimized compound, BAY1217224, has reached first clinical trials, which have confirmed the desired pharmacokinetic properties.

Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors

The invention is concerned with novel heterobicyclic derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, V, W, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.